What Is the Prognosis When Prostate Cancer Spreads to Lymph Nodes?

Cancer in the lymph nodes sounds like the worst news, but when prostate cancer has reached only the nodes near the prostate, most men live many years and treatment can still aim for cure. Lymph-node spread usually behaves more gently than spread to bone or organs, which is why it is staged separately and carries a better outlook. Where the affected nodes sit and how much cancer they hold shape the outcome far more than the bare fact that nodes are involved.

Survival Numbers for Cancer in the Pelvic Lymph Nodes

The prostate drains first into lymph nodes in the pelvis, so these are usually the first place the cancer travels. Among men found at surgery to have cancer in those nodes, half were still alive 15 years later.1PubMed. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results In another group, about 94% were free of prostate cancer death at 5 years and 83% at 10 years.2PubMed. Risk of prostate carcinoma death in patients with lymph node metastasis

Those survival figures count only deaths from prostate cancer. Many men in this age group die of heart disease or other causes first, so how long you live from any cause also depends on general health.

The cancer does come back in some men, in symptoms or on scans: about 20% by 5 years, 35% by 10 years and 42% by 15 years.1PubMed. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results A return is not the same as dying of the disease. It usually shows up first as a PSA blood test that begins to climb, often years before any symptom or visible spot on a scan. A rising PSA is a cue to look for where the cancer is, commonly with a PSMA PET scan. What happens next depends on the findings. A few nodes can be treated with radiation, and a widespread return is usually treated with hormone therapy. Many men live years after a return, often with repeat treatments.

A percentage like 83% at 10 years describes a group of men, not a personal countdown. These numbers also come from men treated years ago, before newer drugs and scans. When a study reports median survival, it means half the men lived longer than that figure.

Doctors also separate regional nodes, the nearby pelvic ones, from distant (nonregional) nodes, such as those in the abdomen or chest. Cancer in distant nodes counts as metastatic disease, which changes the stage and the treatment plan.3American Journal of Roentgenology (AJR). Understanding the Lymphatics: An Updated Review of the N Category of the AJCC 8th Edition for Urogenital Cancers Check which kind your report describes. Staging reports often write N1 for pelvic nodes and M1a for distant nodes.

What Makes the Outlook Better or Worse

The count of cancerous nodes matters a great deal. Men with a single cancerous node did especially well, with 94% free of prostate cancer death at 10 years.2PubMed. Risk of prostate carcinoma death in patients with lymph node metastasis In high-risk cancer, 87% of men with 0 to 3 positive nodes avoided prostate cancer death at 10 years, compared with 50% of men with 4 or more.4PubMed Central. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection Overall survival at 10 years was 72% with 0 to 3 positive nodes and 37% with 4 or more.4PubMed Central. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection Having two or more positive nodes was another useful dividing line for a worse outlook.5PubMed. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection

Doctors also look at the share of removed nodes that contain cancer. When about 30% or more of the removed nodes held cancer, the outlook was clearly worse.5PubMed. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection The total amount of cancer inside the nodes predicted spread and survival better than other node features.6PubMed. Extranodal extension in lymph node-positive prostate cancer Aggressive-looking cancer under the microscope, shown by a high Gleason score or grade group, also worsens the outlook.7PubMed. Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer

Your pathology report puts these details in your hands. The node line usually says how many nodes were removed and how many contained cancer, written as something like 2 of 18. Divide the positive count by the total to get the share affected: 2 of 18 is about 11%, well under the 30% mark. The size of the largest deposit, often listed in millimeters, hints at how much cancer is there. It is also worth asking whether the positive nodes were on one side of the pelvis or both, since that bears on how radiation is planned.

The term extranodal extension sounds alarming. It means the cancer has grown through the node’s outer wall into the fat around it. Yet it did not lower survival once the amount of cancer in the nodes was taken into account, with 5-year survival of about 95% either way.8Modern Pathology. Extranodal Extension in Lymph Node–Positive Prostate Cancer If the report mentions it, the more useful questions are how many nodes were positive and how much cancer they held. Your team may still note it when planning radiation, so it is not something to ignore, only something not to read alone as bad news.

Counts can also differ between men for a simple reason. A more extended operation removes more nodes and so finds more positive ones. That can look worse on paper but gives a more accurate picture of where the cancer is.

How Lymph-Only Spread Compares With Bone or Organ Spread

Among men whose cancer had already spread when it was found, those with spread only to lymph nodes lived longest, a median of about 43 months overall.9PubMed. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer Median survival was about 24 months with bone spread and 16 months with organ spread.9PubMed. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer Liver spread carried the worst outlook in another large group.10Duke Health. Where Prostate Cancer Spreads In the Body Affects Survival Time Lymph-node-only cancer tends to respond well, and for longer, to hormone therapy than bone disease does.11PubMed Central. Influence of Nonregional Lymph Node Metastasis as a Prognostic Factor in Metastatic Prostate Cancer Patients

These months look far shorter than the years in the earlier numbers because they describe different men. These men already had cancer beyond the prostate area when it was first found, so they began with more advanced disease. The men in the earlier figures had pelvic node spread discovered at surgery, and many were treated with the aim of cure.

Distant nodes are a more advanced pattern than pelvic nodes, and they shorten the time before hormone therapy stops working.11PubMed Central. Influence of Nonregional Lymph Node Metastasis as a Prognostic Factor in Metastatic Prostate Cancer Patients Even so, men with distant nodes alone lived longer in these figures than men with bone spread. Bone scans and PSMA PET help show whether any bone is involved, and a finding of nodes only is an encouraging one.

Treatments That Improve Survival

Hormone therapy, called androgen deprivation therapy or ADT, lowers testosterone, which prostate cancer needs in order to grow. For cancer in pelvic nodes found before surgery, the best-established treatment is ADT plus radiation to both the prostate and the pelvic nodes.12PubMed Central. Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options After surgery, radiation to the pelvic nodes and prostate area with long-term ADT can still cure node-positive cancer.13PubMed. Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN-4 and PLATIN-5 Trials Adding pelvic node radiation to radiation of the prostate area after surgery cut the risk of death by about 70%.14PubMed. Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node-Positive Prostate Cancer and Mortality Risk

In practice, radiation is given in short daily sessions on weekdays over several weeks, with the beam covering the prostate area and the pelvic nodes. Hormone therapy is usually an injection every one to six months, depending on the type your doctor chooses. It often starts before or alongside radiation and commonly continues for a year and a half to three years, so it is a long course.

Abiraterone adds more. Two years of abiraterone pills with prednisone added to ADT lowered the risk of death by about 40% in high-risk cancer that hadn’t spread beyond pelvic nodes.15The Journal of Hematology Oncology Pharmacy. Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer16PubMed. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol The benefit held whether or not nodes were involved.15The Journal of Hematology Oncology Pharmacy. Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer Adding enzalutamide on top brought no extra benefit and more side effects.15The Journal of Hematology Oncology Pharmacy. Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer

Abiraterone is a pill taken once a day with prednisone, a low-dose steroid. It is taken alongside hormone therapy, not instead of it, for a set two years. Because it blocks other sources of testosterone-type hormones, your team checks blood pressure, potassium and liver tests during treatment. Ask whether abiraterone is recommended for your situation.

Access to treatment plays a part too. Men who were older, poorer, Black, or uninsured were less likely to get surgery or radiation to the prostate, and much of their lower survival shrank once the treatment they received was accounted for.17PubMed. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer If local treatment isn’t offered, ask why and consider a second opinion. Other questions worth bringing to the oncologist: will radiation cover the pelvic nodes as well as the prostate, and how long will I stay on hormone therapy?

Tracking Progress With PSA and Scans

PSA is a protein made by prostate cells. It is measured in a blood test and rises when cancer grows. After surgery it should fall to a very low level, because the prostate that made most of it is gone, so any steady rise is meaningful. On hormone therapy it usually falls sharply, and how low and how fast is a clue to how well the cancer responds. A low PSA that stays low for a long time is the usual sign that treatment is working.

A PSA that stays at or above 0.2 at its lowest point on hormone therapy, or bottoms out within 6 months, points to an earlier loss of response.18Trends in Urology and Nephrology Research. PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer Eventually the cancer may become castration-resistant, meaning it keeps growing despite low testosterone. The sooner this happens, the shorter survival tends to be.7PubMed. Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer19PubMed. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Tests are usually every three to six months at first, and the schedule may stretch out if results stay low. Lab results vary a little from test to test, so a single small bump does not by itself mean the cancer is growing. The trend over several tests tells more, which is why doctors often repeat a test before acting. Ask what PSA level would lead to a scan or a change in treatment, so you know in advance what would trigger action.

PSA says whether cancer is active but not where it is, and that is the job of scans. PSMA PET scans find cancerous nodes far better than standard CT, about 87% versus 26% in one comparison.20PubMed Central. PSMA PET/CT for prostate cancer diagnosis: current applications and future directions They still miss many small nodes, especially those under about 5 mm,20PubMed Central. PSMA PET/CT for prostate cancer diagnosis: current applications and future directions so a clear scan does not fully rule out tiny node spread.

When only a few spots show up in nodes, focused radiation can treat them. It controls them well and can delay starting hormone therapy.21PubMed. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience New spots often appear elsewhere, though, usually in other nodes.22PubMed. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences

Leg and Genital Swelling After Node Treatment

Removing or radiating pelvic nodes can slow fluid drainage, causing swelling called lymphedema. After node removal alone, leg swelling affected up to 14% and genital swelling up to 1%.23PubMed Central. The Prevalence of Lower Limb and Genital Lymphedema after Prostate Cancer Treatment: A Systematic Review With both node removal and pelvic radiation, leg swelling reached 18% to 29% and genital swelling up to 22%.23PubMed Central. The Prevalence of Lower Limb and Genital Lymphedema after Prostate Cancer Treatment: A Systematic Review It often began about two years after radiation, so it can appear late.24PubMed Central. Incidence and predictors of lower extremity lymphedema after postoperative radiotherapy for prostate cancer

Early signs are subtle: socks leaving a deeper line than usual, a leg that feels heavy or tight at the end of the day, or shoes that fit more snugly. It usually affects one leg rather than both,24PubMed Central. Incidence and predictors of lower extremity lymphedema after postoperative radiotherapy for prostate cancer which is one clue that sets it apart from swelling caused by heart or kidney problems, which tends to appear on both sides, though it can affect both legs. Because it can begin years after treatment, a new swelling long afterward still deserves a report to your team. Early compression and therapy work best.

Once swelling starts, a therapist trained in lymphedema care can teach gentle massage that moves fluid and can fit compression garments. Regular movement, such as walking, helps fluid drain from the legs. Swollen skin is more prone to infection, so clean and watch any cuts or cracks, and have sudden redness, warmth or fever seen quickly.

Hormone therapy brings its own side effects. Hot flashes and tiredness are common, and lower sex drive and erection problems are frequent. Bone thinning and weight gain can occur, and regular exercise helps with both.